(MedPage Today) — The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the agency announced on Thursday.
An adeno-associated virus vector-based gene therapy, lunsotogene parvec…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
